EP4719982A2 - Funktionalisierte kohlenstoffallotrope zur behandlung von homocystein und cysteinbedingten erkrankungen und leiden - Google Patents

Funktionalisierte kohlenstoffallotrope zur behandlung von homocystein und cysteinbedingten erkrankungen und leiden

Info

Publication number
EP4719982A2
EP4719982A2 EP24816372.7A EP24816372A EP4719982A2 EP 4719982 A2 EP4719982 A2 EP 4719982A2 EP 24816372 A EP24816372 A EP 24816372A EP 4719982 A2 EP4719982 A2 EP 4719982A2
Authority
EP
European Patent Office
Prior art keywords
functionalized
composition
manufacture
article
fca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24816372.7A
Other languages
English (en)
French (fr)
Inventor
Vijay Krishna
Prajakatta MULAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of EP4719982A2 publication Critical patent/EP4719982A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/15—Nano-sized carbon materials
    • C01B32/158—Carbon nanotubes
    • C01B32/168—After-treatment
    • C01B32/174—Derivatisation; Solubilisation; Dispersion in solvents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Materials Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP24816372.7A 2023-05-30 2024-05-30 Funktionalisierte kohlenstoffallotrope zur behandlung von homocystein und cysteinbedingten erkrankungen und leiden Pending EP4719982A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363504842P 2023-05-30 2023-05-30
PCT/US2024/031559 WO2024249561A2 (en) 2023-05-30 2024-05-30 Functionalized carbon allotropes for treating homocysteine and cysteine related diseases and conditions

Publications (1)

Publication Number Publication Date
EP4719982A2 true EP4719982A2 (de) 2026-04-08

Family

ID=93658825

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24816372.7A Pending EP4719982A2 (de) 2023-05-30 2024-05-30 Funktionalisierte kohlenstoffallotrope zur behandlung von homocystein und cysteinbedingten erkrankungen und leiden

Country Status (2)

Country Link
EP (1) EP4719982A2 (de)
WO (1) WO2024249561A2 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
NZ545314A (en) * 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
US20210378982A1 (en) * 2018-09-24 2021-12-09 The Cleveland Clinic Foundation Fullerenes to treat diseases and conditions

Also Published As

Publication number Publication date
WO2024249561A3 (en) 2025-02-06
WO2024249561A2 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
Yu et al. O2 economizer for inhibiting cell respiration to combat the hypoxia obstacle in tumor treatments
Bourquin et al. Biodistribution, clearance, and long‐term fate of clinically relevant nanomaterials
Zainal-Abidin et al. Doxorubicin loading on functional graphene as a promising nanocarrier using ternary deep eutectic solvent systems
Guo et al. Nanodrugs with intrinsic radioprotective exertion: Turning the double‐edged sword into a single‐edged knife
ES2529060T3 (es) Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
US8603531B2 (en) Nanometer-sized prodrugs of NSAIDs
Roy et al. Exploring the inhibitory and antioxidant effects of fullerene and fullerenol on ribonuclease A
US20130116284A1 (en) Lipoic acid and nitroxide derivatives and uses thereof
JP5796909B2 (ja) アラキドン酸類縁体、及びそれによる鎮痛治療
KR20180129826A (ko) 시스테아민의 조절 방출을 위한 조성물 및 시스테아민 민감성 장애의 전신 치료
WO2017133714A1 (zh) 富勒烯结构在制备治疗帕金森病的药物中的应用
US11331282B2 (en) Ophthalmic composition containing clathrated antioxidant substance, and use thereof
Richard et al. New concepts to fight oxidative stress: nanosized three-dimensional supramolecular antioxidant assemblies
Thanki et al. Improved oral bioavailability and gastrointestinal stability of amphotericin B through fatty acid conjugation approach
HK1217175A1 (zh) 用於由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物
JP2017505325A (ja) 亜鉛プロトポルフィリンの微粒子送達のための製剤
Lu et al. Current Status and Future Prospects of Hydrogen Sulfide Donor‐Based Delivery Systems
Liu et al. Recent progress of surface modified nanomaterials for scavenging reactive oxygen species in organism
CN105640931A (zh) 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物
Zhao et al. Penetrating the blood–brain barrier for targeted treatment of neurotoxicant poisoning by nanosustained-released 2-PAM@ VB1-MIL-101-NH2 (Fe)
JP7740810B2 (ja) 呼吸困難に起因する集中治療後の認知機能障害及び認知障害の予防及び治療のための化合物
JP2022535920A (ja) 中枢神経系障害を処置するための組成物および方法
CN107823145A (zh) 一种注射用伊潘立酮plga微球及制备工艺
Wang et al. Cell-membrane coated self-immolative poly (thiourethane) for cysteine/homocysteine-triggered intracellular H2S delivery
WO2024249561A2 (en) Functionalized carbon allotropes for treating homocysteine and cysteine related diseases and conditions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR